Axsome Therapeutics specializes in developing and commercializing innovative pharmaceutical products targeting central nervous system disorders. Its prominent commercial portfolio includes Auvelity, an advanced extended-release tablet formulated for major depressive disorder, and Sunosi, a wakefulness-promoting medication prescribed for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Additionally, the company maintains a robust clinical pipeline evaluating novel therapeutic candidates for migraine, Alzheimer's disease agitation, and other neurological conditions.